ORIC Pharmaceuticals has been granted a patent for compounds that inhibit Polo Like Kinase 4 (PLK4), potentially useful in treating cancer. The patent also covers pharmaceutical compositions and methods of treatment involving these compounds. GlobalData’s report on ORIC Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights ORIC Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ORIC Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. ORIC Pharmaceuticals's grant share as of February 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11858915B2) includes a series of claims related to a compound selected from a specific group. The claims outline various aspects of the compound, such as its form, composition, and pharmaceutical applications. Additionally, the patent includes a claim for a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof, along with other pharmaceutical excipients.

The patent's claims provide detailed information about the compound's characteristics and its potential use in pharmaceutical compositions. The inclusion of specific details in the claims helps in defining the scope and boundaries of the patent protection granted for the compound. Furthermore, the claim for a pharmaceutical composition highlights the practical application of the compound in the field of medicine, emphasizing its potential as a key ingredient in the development of new drugs. Overall, the patent serves as a valuable asset in the field of pharmaceutical research and development, offering protection for the compound and its pharmaceutical compositions.

To know more about GlobalData’s detailed insights on ORIC Pharmaceuticals, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies